Equities

Ribomic Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4591:TYO

Ribomic Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)86.00
  • Today's Change3.00 / 3.61%
  • Shares traded510.00k
  • 1 Year change-5.49%
  • Beta0.5256
Data delayed at least 15 minutes, as of Feb 10 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-1.05bn
  • Incorporated2003
  • Employees25.00
  • Location
    Ribomic Inc6F, Shirokanedai Usui Bldg.3-16-13, ShirokanedaiMINATO-KU 108-0071JapanJPN
  • Phone+81 334403303
  • Fax+81 334403729
  • Websitehttps://www.ribomic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PhoenixBio Co Ltd1.51bn-311.88m1.95bn69.00--1.41--1.29-78.53-78.53372.28339.410.65130.95296.9621,877,380.00-13.46-4.25-16.43-5.5775.8467.17-20.66-7.192.91--0.2067---10.143.29-1,801.92--1.08--
Kringle Pharma Inc72.22m-916.26m2.81bn17.00--2.05--38.88-133.98-133.9810.55186.560.0299--1.224,247,941.00-37.89-23.52-39.85-24.93-----1,268.79-349.8916.51-5,167.340.00---9.77-31.17-21.13------
Veritas In Silico Inc95.43m-376.29m3.22bn19.00--1.67--33.72-58.00-58.0014.71296.600.0442----5,022,579.00-17.42---17.81-------394.31--31.68--0.00---45.99---815.45------
NPT Co Ltd0.00-266.47m3.41bn6.00--43.82-----54.98-54.980.0015.980.00-------318.44---439.04-------------2,152.880.00-------68.67------
FunPep Co Ltd2.94m-1.56bn4.10bn15.00--1.92--1,395.42-44.48-44.480.081552.710.0010.0467--195,733.30-51.62-28.60-60.65-30.4039.68---53,241.21-3,042.404.60-608.880.00--1,056.04-54.124.75---2.98--
Human Metabolome Technologies Inc1.37bn194.67m4.16bn62.0021.812.3613.623.0332.1832.18236.21297.910.63958.698.8622,148,600.009.0710.5411.0113.5961.4266.6514.1817.244.81230.200.060120.988.125.405.42--33.68--
Ribomic Inc0.00-1.05bn4.67bn25.00--1.36-----23.81-23.810.0063.040.00----0.00-31.15-29.95-32.30-31.15-------2,725.9525.20--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.06bn5.07bn14.00--1.72-----27.71-27.710.0033.640.00----0.00-66.07-35.65-74.94-36.83-------1,981.18----0.0888------44.90---67.80--
D.Western Therapeutics Institute Inc419.76m-1.06bn5.53bn21.00--3.70--13.18-24.98-24.989.4827.560.19210.41942.7119,988,760.00-48.31-24.39-52.24-26.5889.7593.00-251.53-142.258.69-274.870.2606--10.09-4.07-58.82------
Carna Biosciences, Inc.579.06m-2.17bn5.97bn63.00--19.31--10.32-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
TMS Co Ltd0.00-670.20m6.50bn18.00--2.17-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Cyfuse Biomedical KK-100.00bn-100.00bn6.75bn21.00--2.27----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m6.76bn25.00--1.64--945.69-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
Data as of Feb 10 2026. Currency figures normalised to Ribomic Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.62%Per cent of shares held by top holders
HolderShares% Held
Evolution Capital Management LLCas of 10 Dec 2025338.30k0.62%
Data from 30 Jan 2026 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.